JP2017537168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537168A5 JP2017537168A5 JP2017549172A JP2017549172A JP2017537168A5 JP 2017537168 A5 JP2017537168 A5 JP 2017537168A5 JP 2017549172 A JP2017549172 A JP 2017549172A JP 2017549172 A JP2017549172 A JP 2017549172A JP 2017537168 A5 JP2017537168 A5 JP 2017537168A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- use according
- core
- cellulose
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 20
- 229920000642 polymer Polymers 0.000 claims 13
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 6
- 229920002678 cellulose Polymers 0.000 claims 6
- 229960000450 esketamine Drugs 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 239000001913 cellulose Substances 0.000 claims 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 4
- 239000011159 matrix material Substances 0.000 claims 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 3
- 229920002125 Sokalan® Polymers 0.000 claims 3
- 229960001631 carbomer Drugs 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000011258 core-shell material Substances 0.000 claims 3
- 229960003299 ketamine Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- 229920002301 cellulose acetate Polymers 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
- BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims 1
- 229920002284 Cellulose triacetate Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 239000007891 compressed tablet Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000002895 emetic Substances 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 231100000021 irritant Toxicity 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000003401 opiate antagonist Substances 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088901P | 2014-12-08 | 2014-12-08 | |
| US62/088,901 | 2014-12-08 | ||
| PCT/US2015/064403 WO2016094358A1 (en) | 2014-12-08 | 2015-12-08 | Immediate release abuse-deterrent granulated dosage forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537168A JP2017537168A (ja) | 2017-12-14 |
| JP2017537168A5 true JP2017537168A5 (OSRAM) | 2019-06-13 |
| JP6696994B2 JP6696994B2 (ja) | 2020-05-20 |
Family
ID=56108034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549172A Active JP6696994B2 (ja) | 2014-12-08 | 2015-12-08 | 即放性乱用抑止性顆粒剤形 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US9827204B2 (OSRAM) |
| EP (1) | EP3229788A4 (OSRAM) |
| JP (1) | JP6696994B2 (OSRAM) |
| CA (1) | CA2970065A1 (OSRAM) |
| IL (1) | IL252708A0 (OSRAM) |
| WO (1) | WO2016094358A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| CA2938699A1 (en) | 2014-02-05 | 2015-08-13 | Kashiv Pharma Llc | Abuse-resistant drug formulations with built-in overdose protection |
| WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| JP2019513707A (ja) | 2016-04-11 | 2019-05-30 | クレキシオ バイオサイエンシーズ エルティーディー． | 重水素化ケタミン誘導体 |
| USD857156S1 (en) * | 2016-11-02 | 2019-08-20 | Innovative Water Care, Llc | Chemical tablet for aquatic systems |
| CA3067945A1 (en) * | 2017-06-23 | 2018-12-27 | Sun Pharma Advanced Research Company Limited | Abuse deterrent oral solid dosage form |
| CN111465396B (zh) | 2017-12-20 | 2024-07-09 | 普渡制药公司 | 防滥用硫酸吗啡剂型 |
| EP3505157B1 (en) | 2017-12-29 | 2021-12-08 | Celon Pharma S.A. | Dry powder ketamine composition for pulmonary administration in treatment-resistant depression |
| EP3813807A1 (en) | 2018-06-27 | 2021-05-05 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| WO2020070547A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| CA3113198A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| WO2020070706A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| US12364672B2 (en) | 2018-10-11 | 2025-07-22 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| US20220062200A1 (en) * | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| WO2021137148A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| IL293506A (en) | 2019-12-30 | 2022-08-01 | Clexio Biosciences Ltd | Dosage regime with esketamine for treating major depressive disorder |
| USD943706S1 (en) * | 2020-06-10 | 2022-02-15 | Emily Florence Johns | Shower steamer |
| WO2025057111A1 (en) | 2023-09-12 | 2025-03-20 | Clexio Biosciences Ltd. | Esketamine or a pharmaceutical salt thereof for use in a method of treating major depressive disorder |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US5679714A (en) * | 1995-06-07 | 1997-10-21 | Weg; Stuart L. | Administration of ketamine for detoxification and treatment of tobacco addiction |
| ES2540103T3 (es) | 2000-02-08 | 2015-07-08 | Euro-Celtique S.A. | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas |
| US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
| US6608159B2 (en) | 2001-09-18 | 2003-08-19 | Skw Polymers Gmbh | Polymeric, acrylamide-free water retention agent |
| US20040081695A1 (en) * | 2002-09-28 | 2004-04-29 | Sowden Harry S | Dosage forms having an inner core and an outer shell |
| NZ546226A (en) * | 2003-09-30 | 2009-03-31 | Shire Llc | Oxycodone conjugates for prevention of overdose or abuse |
| WO2005056619A1 (en) | 2003-12-15 | 2005-06-23 | Council Of Scientific & Industrial Research | pH SENSITIVE POLYMER AND PROCESS FOR PREPARATION THEREOF |
| EP2332420A3 (en) | 2005-12-09 | 2013-08-21 | Marel Stork Poultry Processing B.V. | Method and device for processing a carcass part of slaughtered poultry |
| ES2600141T3 (es) | 2006-06-19 | 2017-02-07 | Alpharma Pharmaceuticals Llc | Composiciones farmacéuticas |
| DK2046300T3 (da) | 2006-08-04 | 2010-07-26 | Ethypharm Sa | Oralt desintegrerende multilagstablet |
| WO2008024490A2 (en) * | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| EP2057984B1 (de) * | 2007-11-09 | 2010-01-20 | Acino Pharma AG | Retardtabletten mit Hydromorphon |
| CA2664772C (en) | 2009-05-13 | 2010-02-16 | The Procter & Gamble Company | Label applicator having a heat idler |
| CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
| US9211292B2 (en) * | 2010-04-21 | 2015-12-15 | Alitair Pharmaceuticals Inc | Preventing or reducing drug abuse and overdose events |
| EP2675436A1 (en) * | 2011-02-17 | 2013-12-25 | Qrxpharma Limited | Technology for preventing abuse of solid dosage forms |
| EP2782558A4 (en) | 2011-11-22 | 2015-03-18 | Watson Pharmaceuticals Inc | MISSABLE TABLET WITH IMMEDIATE RELEASE |
| KR101257207B1 (ko) | 2012-02-23 | 2013-04-22 | 인텔 코오퍼레이션 | 헤드 트래킹 방법, 장치 및 컴퓨터 판독 가능한 기록 매체 |
| JP6137168B2 (ja) | 2012-02-29 | 2017-05-31 | パナソニックＩｐマネジメント株式会社 | データ取得システム |
| EP2819653B1 (en) * | 2012-03-02 | 2017-01-11 | Rhodes Pharmaceuticals L.P. | Tamper resistant immediate release formulations |
| KR20140136982A (ko) * | 2012-03-12 | 2014-12-01 | 얀센 파마슈티카 엔.브이. | 치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민 |
| WO2014020155A1 (en) * | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
| EP2925304B1 (en) * | 2012-11-30 | 2018-09-05 | Acura Pharmaceuticals, Inc. | Self-regulated release of active pharmaceutical ingredient |
| FR2999426B1 (fr) * | 2012-12-13 | 2015-01-02 | Flamel Tech Sa | Forme orale multiparticulaire a liberation immediate d'au moins un compose actif, comprenant des particules enrobees resistantes au broyage. |
| US10751287B2 (en) * | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US9913803B2 (en) | 2013-08-26 | 2018-03-13 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| WO2015065547A1 (en) * | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| WO2015066172A1 (en) * | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| CA2938699A1 (en) * | 2014-02-05 | 2015-08-13 | Kashiv Pharma Llc | Abuse-resistant drug formulations with built-in overdose protection |
| WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| US20170157052A1 (en) | 2015-12-08 | 2017-06-08 | Cima Labs Inc. | Immediate release dosage forms that deter abuse by oral ingestion of multiple dosage units |
-
2015
- 2015-12-08 WO PCT/US2015/064403 patent/WO2016094358A1/en not_active Ceased
- 2015-12-08 JP JP2017549172A patent/JP6696994B2/ja active Active
- 2015-12-08 EP EP15867664.3A patent/EP3229788A4/en not_active Withdrawn
- 2015-12-08 CA CA2970065A patent/CA2970065A1/en not_active Abandoned
-
2016
- 2016-07-14 US US15/210,760 patent/US9827204B2/en active Active
-
2017
- 2017-02-02 US US15/423,388 patent/US10201505B2/en active Active
- 2017-06-06 IL IL252708A patent/IL252708A0/en unknown
-
2019
- 2019-01-07 US US16/241,102 patent/US10888528B2/en active Active
-
2020
- 2020-12-03 US US17/110,808 patent/US11730702B2/en active Active
-
2021
- 2021-12-22 US US17/559,158 patent/US11534409B2/en active Active
-
2023
- 2023-05-25 US US18/323,474 patent/US20230293445A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537168A5 (OSRAM) | ||
| JP2017128614A5 (OSRAM) | ||
| JP2016535773A5 (OSRAM) | ||
| Debunne et al. | Compaction of enteric-coated pellets: influence of formulation and process parameters on tablet properties and in vivo evaluation | |
| JP2012153724A5 (OSRAM) | ||
| Hosseini et al. | Direct compression of cushion-layered ethyl cellulose-coated extended release pellets into rapidly disintegrating tablets without changes in the release profile | |
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| JP2013540807A5 (OSRAM) | ||
| JP2013522219A5 (OSRAM) | ||
| JP2008511604A5 (OSRAM) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| CN102316857A (zh) | 防止误用的控释配方 | |
| JP2014528431A5 (OSRAM) | ||
| JP2016539953A5 (OSRAM) | ||
| CN102883601A (zh) | 金刚烷胺组合物及其使用方法 | |
| EA031255B1 (ru) | Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения | |
| RU2010109408A (ru) | Композиции с пролонгированным высвобождением, включающие микофенолят натрия, и их действия | |
| CA3021071A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| JP2015509539A5 (OSRAM) | ||
| JP5973347B2 (ja) | 口腔内崩壊錠 | |
| JP2011516544A5 (OSRAM) | ||
| JP2015120758A5 (OSRAM) | ||
| JP2019513801A5 (OSRAM) | ||
| CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| US20200155461A1 (en) | Oral pharmaceutical compositions of nicotinamide |